Follow up study of patients at increased risk of developing cancer
In collaboration with Columbia University’s First Cell Center for Cancer Surivors (FiCCCS), Rarecells will test blood samples of cancer survivors. This population is at higher risk of developing cancer. In fact, when adjusted for age and sex, the probability of a second new cancer among cancer survivors is twice as high as that in an individual who was never diagnosed with cancer. The collaboration will support the creation and management of a new biorepository of patients’ samples and enable next-generation sequencing analyses of ctDNA and ctcDNA in cancer survivors as a way to validate a multi-cancer non- invasive early diagnosis test.
Size of cohort: 48,000 patients